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OBJECTIVES: To determine cost and outcomes of a diabetes
clinic in a community hospital of Mae Hong Son Province in
1999. METHODS: A retrospective study, from the provider
viewpoint, was performed by collecting three groups of annual
operating cost; labour cost (LC), drug and medical supplies cost
(MC), and diagnostic cost (DC). The clinic contained of behav-
ioral group counseling about diet, drug, exercise and foot-care
by nurses, pharmacist and self-help group. At the end of the
study, outcomes were evaluated by the number of patient who
achieved in the fasting blood sugar (FBS) of 126mg/dL without
any severe complications and/or the number of patient with
adherence for follow up visits. RESULTS: Results showed that
total operating cost of diabetes clinic was 193,244.64 Baht with
a proportion of LC:MC:DC of 2.36 :5.55 :1. Drug and medical
supplies accounted for more than 60% of total operating cost.
The unit cost of diabetes clinic was 1932.45 Baht per patient. In
total, 62 patients with FBS control and 71 patients with adher-
ence for follow-up were found from all of 100 diabetic patients
in the clinic. A total of 33 successful patients with both FBS
control without severe complications and having adherence were
found. Uncontrol FBS and loss from follow up were the failures
that affected to the cost through drug and medical supplies
overuse and the number of unwanted admissions. CONCLU-
SIONS: Drug and medical supplies accounted for the highest cost
of the clinic. To reduce cost of drug and medical supplies overuse
and increase the outcomes of the clinic, drug and self-care per-
sonal counseling by pharmacist could be a good procedure for
solving the problem. To evaluate the efﬁciency of the clinic, cost
and outcomes were the needed indicators.
PDB21
ECONOMIC VALUE OF ACARBOSE TREATMENT IN PERSONS
WITH IMPAIRED GLUCOSE TOLERANCE (IGT) FOR THE
GERMAN HEALTH CARE SYSTEM
Evers T1, Lüddeke HJ2, Liebl A3, Kotowa W4, Maclaine G5
1Bayer Vital GmbH, Leverkusen, Germany; 2Diabetische
Schwerpunktpraxis, Munich, Germany; 3Fachklinik Bad Heilbrunn, Bad
Heilbrunn, Germany; 4Fricke & Pirk GmbH, Nuremberg, Germany;
5Bayer plc, Uxbridge, UK
OBJECTIVES: The Study TO Prevent Non-Insulin Dependent
Diabetes Mellitus (STOP-NIDDM) demonstrated that acarbose
therapy over 3.3 years delays or prevents the development of
type-2 diabetes as well as cardiovascular (CV) events in persons
with impaired glucose tolerance (IGT). The aim of the present
study is to assess the economic advantage of these clinical results
for the German health care system. METHODS: A cost-
effectiveness-analysis from the German payers’ perspective was
conducted. The outcome measure was cost per transition to dia-
betes prevented or delayed. Analyses were conducted for the
total population (acarbose (N = 682) and placebo (N = 686)),
and subgroups at high risk for CV disease, for diabetes or both.
Cost data were derived from published sources and adjusted to
the year 2003 where necessary. Future costs and beneﬁts were
discounted by 5%. Acarbose therapy costs and the costs for man-
aging new cases of diabetes, hypertension, and CV events were
taken into account. Only direct healthcare costs were considered.
RESULTS: For the total population treated over 3.3 years, the
incremental cost-effectiveness-ratio was 772€ per case of dia-
betes delayed. For all high-risk subgroups, acarbose treatment
was the dominant treatment option: Cost savings per person in
the subgroup at high risk for CV disease, for diabetes and for
both CV disease and diabetes were 674€, 42€ and 408€ respec-
tively over 3.3 years. These results were robust to sensitivity
analyses. CONCLUSIONS: In addition to the signiﬁcant clinical
beneﬁts observed with acarbose therapy in pre-diabetic persons,
the cost-effectiveness model estimated potential cost savings to
the German healthcare system in those persons at high risk for
diabetes and / or cardiovascular events. For the total population,
acarbose therapy was estimated to be cost-effective.
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OBJECTIVES: Metformin (plus standard lifestyle advice) or
intensive lifestyle changes (ILC) reduced the risk of developing
Type-2 diabetes by 31% and 58% versus standard lifestyle
advice (control) respectively, in subjects with impaired glucose
tolerance (IGT) in the Diabetes Prevention Program (DPP). We
adapted a validated, peer-reviewed, published diabetes preven-
tion model to assess the cost-effectiveness of DPP interventions
in a Spanish setting. METHODS: The published Markov model
simulated 3 states; patients progressed from “IGT” to “Type-2
diabetes” and “death”. Probabilities were derived from the DPP
and published Spanish data. Life expectancy (LE) was calculated
for each treatment arm. Spanish-speciﬁc direct costs of imple-
menting DPP interventions and of diabetes were retrieved from
published sources. Total costs/patient (TC) and costs/life-year
gained were calculated. LE was discounted at both 0 and 3%
annually, while costs were discounted at 3% annually in accor-
dance with current Spanish guidelines. Extensive sensitivity
analyses were performed. RESULTS: Both interventions
improved LE but increased TC versus control. Mean improve-
ments in non-discounted LE were 0.33 and 0.87 years for met-
formin and ILC, respectively. TC were increased by 626€ and
8784€/patient with metformin or ILC respectively, with incre-
mental costs/life-year gained (LYG) (TC and LE discounted 3%
annually) of 3913€ and 22,523€ for metformin or ILC versus
control, respectively. Results were most sensitive to the costs of
implementing ILC (in particular, the costs associated with dieti-
cians). CONCLUSIONS: Metformin was cost-effective, and the
initial costs of pharmacological intervention in prediabetic indi-
viduals should not deter healthcare systems from implementing
diabetes prevention programs. ILC was towards the upper limits
of what is generally considered good value for money in Spain
(i.e. <30,000€/LYG). If the role of lifestyle case managers was
played by less expensive personnel (e.g. a ﬁtness trainer), the
incremental cost-effectiveness ratio for ILC versus control could
be as low as 9185€/LYG.
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OBJECTIVES: To assess the cost-effectiveness of acarbose in the
management of patients with impaired glucose tolerance (IGT)
in Sweden using the multinational, randomised, placebo-
controlled STOP-NIDDM trial, in which patients with IGT
treated with acarbose experienced signiﬁcant reductions in the
incidence of type-2 diabetes and cardiovascular (CV) events.
METHODS: A disease state transition model using data from
